Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 11/2019

01-11-2019 | Care | Original Paper

Metabolic Syndrome Among People Living with HIV Receiving Medical Care in Southern United States: Prevalence and Risk Factors

Authors: Sabeena Sears, Justin R. Buendia, Sylvia Odem, Mina Qobadi, Pascale Wortley, Osaro Mgbere, Jontae Sanders, Emma C. Spencer, Arti Barnes

Published in: AIDS and Behavior | Issue 11/2019

Login to get access

Abstract

Using representative data among 1861 in care people living with HIV (PLWH) in four southern states (Texas, Mississippi, Florida, and Georgia) from the 2013–2014 Medical Monitoring Project (MMP) survey, we estimated the prevalence and odds of metabolic syndrome (MetS) among various demographic and HIV related risk factors. Overall MetS prevalence was 34%, with our participants being mostly black (55%), male (72%), ≥ 50 years old (46%), and overweight or obese (60%) with undetectable viral loads (≤ 200 copies/ml, 69%), and were currently taking antiretroviral medication (98%). Compared to those who were ≥ 60 years, 18–39 year olds had a 79% (95% CI 0.13–0.33) lower odds of having MetS. Women were 2.24 times more likely to have MetS than men (95% CI 1.69–2.97). Age and sex were significant predictors of MetS. Since MetS is a combination of chronic disease risk factors, regular screening for MetS risk factors among aging PLWH is crucial.
Literature
1.
Grinsztejn B, Luz PM, Pacheco AG, et al. Changing mortality profile among HIV-infected patients in Rio de Janeiro, Brazil: shifting from AIDS to non-AIDS related conditions in the HAART era. PLoS ONE. 2013;8(4):e59768.PubMedPubMedCentralCrossRef
2.
Martin-Iguacel R, Negredo E, Peck R, Friis-Møller N. Hypertension is a key feature of the metabolic syndrome in subjects aging with HIV. Curr Hypertens Rep. 2016;18(6):46.PubMedPubMedCentralCrossRef
3.
Murray CJ, Ortblad KF, Guinovart C, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9947):1005–70.PubMedPubMedCentralCrossRef
4.
Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338(13):853–60.PubMedCrossRef
5.
Expert Panel on Detection E. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486.CrossRef
6.
Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28(7):1769–78.PubMedCrossRef
7.
8.
Sperling LS, Mechanick JI, Neeland IJ, et al. The cardiometabolic health alliance: working toward a new care model for the metabolic syndrome. J Am Coll Cardiol. 2015;66(9):1050–67.PubMedCrossRef
9.
Paula AA, Falcão MC, Pacheco AG. Metabolic syndrome in HIV-infected individuals: underlying mechanisms and epidemiological aspects. AIDS Res Ther. 2013;10(1):32.PubMedPubMedCentralCrossRef
10.
Branson BM, Owen SM, Wesolowski LG, et al. Laboratory testing for the diagnosis of HIV infection: updated recommendations. 2014.
11.
Jaggers JR, Prasad VK, Dudgeon WD, et al. Associations between physical activity and sedentary time on components of metabolic syndrome among adults with HIV. AIDS Care. 2014;26(11):1387–92.PubMedPubMedCentralCrossRef
12.
Jericó C, Knobel H, Montero M, et al. Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care. 2005;28(1):132–7.PubMedCrossRef
13.
14.
Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. Aids. 1998;12(7):F51–8.PubMedCrossRef
15.
Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146–603.PubMedPubMedCentralCrossRef
16.
Farahani M, Mulinder H, Farahani A, Marlink R. Prevalence and distribution of non-AIDS causes of death among HIV-infected individuals receiving antiretroviral therapy: a systematic review and meta-analysis. Int J STD AIDS. 2017;28(7):636–50.PubMedCrossRef
17.
Data Collection on Adverse Events of Anti-HIV drugs (D: A: D) Study Group. Factors associated with specific causes of death amongst HIV-positive individuals in the D: A: D Study. Aids. 2010;24(10):1537–48.CrossRef
18.
Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349(21):1993–2003.PubMedCrossRef
19.
Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92(7):2506–12.PubMedCrossRef
20.
Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case–control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med. 2010;170(14):1228–38.PubMedCrossRef
21.
Chow FC, Regan S, Feske S, Meigs JB, Grinspoon SK, Triant VA. Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a U.S. Health Care System. J Acquir Immune Defic Syndr (1999). 2012;60(4):351–8.CrossRef
22.
CfD Control. Prevention. National diabetes statistics report, 2017. Atlanta, GA: Centers for Disease Control and Prevention; 2017. p. 2017.
23.
Tien PC, Schneider MF, Cox C, et al. Association of HIV infection with incident diabetes mellitus: impact of using hemoglobin A1C as a criterion for diabetes. J Acquir Immune Defic Syndr (1999). 2012;61(3):334.CrossRef
24.
Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165(10):1179–84.PubMedCrossRef
25.
Butt AA, McGinnis K, Rodriguez-Barradas MC, et al. HIV infection and the risk of diabetes mellitus. AIDS (London, England). 2009;23(10):1227.PubMedCentralCrossRef
26.
Samaras K. Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy. JAIDS J Acquir Immune Defic Syndr. 2009;50(5):499–505.PubMedCrossRef
27.
Rasmussen LD, Mathiesen ER, Kronborg G, Gerstoft J, Obel N. Risk of diabetes mellitus in persons with and without HIV: a Danish nationwide population-based cohort study. PLoS ONE. 2012;7(9):e44575.PubMedPubMedCentralCrossRef
28.
Rebeiro PF, Gange SJ, Horberg MA, et al. Geographic variations in retention in care among HIV-infected adults in the United States. PLoS ONE. 2016;11(1):e0146119.PubMedPubMedCentralCrossRef
29.
Ezzati M, Martin H, Skjold S, Hoorn SV, Murray CJ. Trends in national and state-level obesity in the USA after correction for self-report bias: analysis of health surveys. J R Soc Med. 2006;99(5):250–7.PubMedPubMedCentralCrossRef
30.
Danaei G, Friedman AB, Oza S, Murray CJ, Ezzati M. Diabetes prevalence and diagnosis in US states: analysis of health surveys. Popul Health Metr. 2009;7(1):16.PubMedPubMedCentralCrossRef
31.
Hicks LS, Fairchild DG, Cook E, Ayanian JZ. Association of region of residence and immigrant status with hypertension, renal failure, cardiovascular disease, and stroke, among African-American participants in the third National Health and Nutrition Examination Survey (NHANES III). Ethn Dis. 2003;13(3):316–23.PubMed
32.
Obisesan TO, Vargas CM, Gillum RF. Geographic variation in stroke risk in the United States: region, urbanization, and hypertension in the Third National Health and Nutrition Examination Survey. Stroke. 2000;31(1):19–25.PubMedCrossRef
33.
Reif SS, Whetten K, Wilson ER, et al. HIV/AIDS in the Southern USA: a disproportionate epidemic. AIDS Care. 2014;26(3):351–9.PubMedCrossRef
34.
Reif S, Safley D, McAllaster C, Wilson E, Whetten K. State of HIV in the US Deep South. J Community Health. 2017;42(5):844–53.PubMedCrossRef
35.
36.
Iachan R, Johnson CH, Harding RL, et al. Design and weighting methods for a nationally representative sample of HIV-infected adults receiving medical care in the United States-Medical Monitoring Project. Open AIDS J. 2016;10:164.PubMedPubMedCentralCrossRef
37.
Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition. A consensus statement from the international diabetes federation. Diab Med. 2006;23(5):469–80.CrossRef
38.
Bozeman SR, Hoaglin DC, Burton TM, Pashos CL, Ben-Joseph RH, Hollenbeak CS. Predicting waist circumference from body mass index. BMC Med Res Methodol. 2012;12(1):115.PubMedPubMedCentralCrossRef
39.
Bernal E, Masia M, Padilla S, Martin-Hidalgo A, Gutierrez F. Prevalence and characteristics of metabolic syndrome among HIV-infected patients from a Mediterranean cohort. Med Clin. 2007;128(5):172–5.CrossRef
40.
Gazzaruso C, Bruno R, Garzaniti A, et al. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens. 2003;21(7):1377–82.PubMedCrossRef
41.
Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and hypoadiponectinemia. Diabetes Care. 2007;30(1):113–9.PubMedCrossRef
42.
Nguyen KA, Peer N, de Villiers A, et al. Metabolic syndrome in people living with human immunodeficiency virus: an assessment of the prevalence and the agreement between diagnostic criteria. Int J Endocrinol. 2017;2017:1613657.PubMedPubMedCentralCrossRef
43.
Jacobson DL, Tang AM, Spiegelman D, et al. Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr (1999). 2006;43(4):458–66.CrossRef
44.
Freimer N, Echenberg D, Kretchmer N. Cultural variation—nutritional and clinical implications. West J Med. 1983;139(6):928–33.PubMedPubMedCentral
45.
Nicolson TJ, Mellor HR, Roberts RR. Gender differences in drug toxicity. Trends Pharmacol Sci. 2010;31(3):108–14.PubMedCrossRef
46.
Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis. 2001;32(1):130–9.PubMedCrossRef
47.
Cerrato E, Calcagno A, D’Ascenzo F, et al. Cardiovascular disease in HIV patients: from bench to bedside and backwards. Open Heart. 2015;2(1):e000174.PubMedPubMedCentralCrossRef
48.
Pernerstorfer-Schoen H, Jilma B, Perschler A, et al. Sex differences in HAART-associated dyslipidaemia. Aids. 2001;15(6):725–34.PubMedCrossRef
49.
Mosca L, Jones WK, King KB, Ouyang P, Redberg RF, Hill MN. Awareness, perception, and knowledge of heart disease risk and prevention among women in the United States. Arch Fam Med. 2000;9(6):506.PubMedCrossRef
50.
Sobieszczyk ME, Hoover DR, Anastos K, et al. Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women’s Interagency HIV Study. J Acquir Immune Defic Syndr (1999). 2008;48(3):272–80.CrossRef
51.
Polotsky HN, Polotsky AJ, editors. Metabolic implications of menopause. Seminars in reproductive medicine; 2010. Stuttgart: Thieme Medical Publishers; 2010.
52.
Akl L, Valadares A, Gomes D, Pinto-Neto A, Costa-Paiva L. Factors associated with metabolic syndrome in middle-aged women with and without HIV. J Metabolic Syndr. 2016;5(200):2167-0943.1000.
53.
Tremollieres FA, Pouilles J-M, Ribot CA. Relative influence of age and menopause on total and regional body composition changes in postmenopausal women. Am J Obstet Gynecol. 1996;175(6):1594–600.PubMedCrossRef
Metadata
Title
Metabolic Syndrome Among People Living with HIV Receiving Medical Care in Southern United States: Prevalence and Risk Factors
Authors
Sabeena Sears
Justin R. Buendia
Sylvia Odem
Mina Qobadi
Pascale Wortley
Osaro Mgbere
Jontae Sanders
Emma C. Spencer
Arti Barnes
Publication date
01-11-2019
Publisher
Springer US
Published in
AIDS and Behavior / Issue 11/2019
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-019-02487-8

Other articles of this Issue 11/2019

AIDS and Behavior 11/2019 Go to the issue

Original Paper

Evaluation of a Computer-Based HIV Education Program for Adults Living with HIV

Original Paper

VITAL Start: Video-Based Intervention to Inspire Treatment Adherence for Life—Pilot of a Novel Video-Based Approach to HIV Counseling for Pregnant Women Living with HIV

Guest Editorial

Ending HIV in America: Not Without the Power of Community

Original Paper

Disparities in Viral Suppression and Medication Adherence among Women in the USA, 2011–2016

Original Paper

Evaluation of Sex Positive! A Video eHealth Intervention for Men Living with HIV

Original Paper

Acceptability and Preliminary Efficacy of an Online HIV Prevention Intervention for Single Young Men Who Have Sex with Men Seeking Partners Online: The myDEx Project
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits